Most Read Articles
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Long-term risk of recurrent stroke high in stroke, TIA survivors with no early complications

17 Aug 2017

Survivors of stroke or transient ischaemic attack (TIA) with no early complications suffer from higher long-term risks of recurrent stroke and admission into an institution, a new study has found.

The study included 26,366 stroke or TIA patients (median age 72 years; 46.9 percent female) who survived for 90 days without complications. Controls (n=263,660; mean age 72 years; 46.9 percent female) were matched for geographic location, sex and age. Rates of composite and individual outcomes of death, stroke, myocardial infarction (MI) or admission to continuing care were calculated at 1, 3 and 5 years.

At 1 year, 9.5 percent of the patients who were event-free at 90 days after stroke or TIA experienced the primary composite outcome.  The 3- and 5-year composite outcome rates were 23.6 and 35.7 percent, respectively. Rates were higher than in the corresponding controls (5.4, 13.6 and 21.1 percent, respectively).

Five-year rates of the secondary outcomes of stroke (7.8 vs 1.6 percent), MI (3.9 vs 2.5 percent), admission to continuing care (8.9 vs 4.7 percent) and death (26.0 vs 16.9 percent) were all higher in cases than in controls.

The risk for the primary outcome in cases was more than twice than in controls at 1 year (hazard ratio [HR], 2.4; 95 percent CI, 2.3 to 2.5). This was consistent at 3 (HR, 2.2; 2.1 to 2.3) and 5 (HR, 2.1; 2.1 to 2.2) years.

Long-term risk of recurrent stroke in cases at 1 (HR, 6.8;6.1 to 7.5), 3 (HR, 5.6; 5.2 to 6.0) and 5 (HR, 5.1; 4.8 to 5.5) years was the highest among all outcomes examined.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Mar 2015
Red yeast rice extracts have been used in traditional medicine for centuries.1 In recent times, an extract from red yeast rice, Xuezhikang® (XZK), has been studied for its role in dyslipidaemia and cardiovascular disease. This review will look at some of the clinical trials that have done so.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).